<DOC>
	<DOCNO>NCT00552058</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy certolizumab pegol induce clinical remission patient moderate severe Crohn 's disease compare placebo base Crohn 's Disease Activity Index ( CDAI ) score Week 6 .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Certolizumab Pegol Induction Remission Patients With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>male/female 18 75 year inclusive diagnosis Crohn 's disease confirm moderate severe disease activity ( Crohn 's Disease Activity Index ( CDAI ) 225 450 ) previous treatment antitumor necrosis factor ( antiTNF ) medication previous participation certolizumab pegol study general exclusion criterion common study indication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>CDP 870</keyword>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>CIMZIA Â®</keyword>
	<keyword>Crohn 's disease</keyword>
	<keyword>Induction</keyword>
	<keyword>Clinical remission</keyword>
	<keyword>Clinical response</keyword>
</DOC>